top of page

Atrial Fibrillation

Atrial fibrillation (AF or Afib) is the most common cardiac arrhythmia affecting millions worldwide.  AF causes the left atrium to fibrillate leading to blood clot formation and increased risk of stroke. 



20%-30% of all strokes occur in AF patients


The lifetime risk of getting AF is 1 in 4

Atrial Fibrillation
Therapy Today

(Catheter Ablation)


AF may be treated with medication, cardioversion or with catheter ablation which is considered the golden standard interventional procedure.   In catheter ablation procedures lesions are formed in the left atrium around the pulmonary veins where the irregular electrical signals are coming from.  Lesions are created with catheters that deliver uniform energy via direct contact with the tissue leading to its destruction and therefore, blockage of the irregular electrical.


The Problem

Existing solutions difficult to use


Heart icon

Up to 40% of patients require 2nd procedure


Atrial Fibrillation Therapy

Tissue contact 
is mandatory


No tissue thickness measurement


No lesion monitoring

The Solution 

No-Contact Guided Ablation

The first product that allows:

Check icon
Check icon
Healium Atrial Fibrillation Solution

Contactless ablation​

Automatic power titration based on tissue thickness​

Check icon

Real-time lesion monitoring

AF Catheter Ablation – Market Opportunity 

AF Market potential


Existing Market potential


Crowd icon

46.1 Millions

Patients worldwide


Heart icon


CAGR 2019-2025



70% Increase

In diagnosed patients by 2030 

Heart icon

>2 Millions

newly diagnosed per year in the US & EU alone



Procedures/year 2018

Heart icon


Market 2025



M&A Since 2008

bottom of page